An advanced monomeric anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) therapy to treat relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) patients.

An anti-cancer cellular vaccine that utilizes patient antigen presenting cells (APCs) pulsed with relevant cancer cells to target the entire repertoire of tumour cell antigens and elicit immune response against hard to treat cancers.

An adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) as a personalized cancer treatment platform via infusion of autologous T lymphocytes expanded from tumors. A complementary cellular biomanufacturing platform is being developed based on a novel metabolic sensor to optimize the harvest time and increase therapeutic potential of the T-cells.

A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.

A CD19/22 bi-specific CAR-T therapy to treat relapsed or refractory B-ALL patients and possibly reduce the risk of long-term relapse.

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

Ranpirnase is a ribonuclease (RNA) degrading enzyme used to target double-stranded RNA including miRNA precursors that has been developed for use with external genital warts (EGW) and anal displaysia using advanced topical formulation.

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

A systemic formulation of Ranpirnase developed as a broad-spectrum antiviral for multiple infectious diseases including human papilloma virus (HPV), human immunodeficiency virus HIV, a range of severe acute respiratory syndromes (SARS) including COVID-19, Ebola and others.

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

Synthetic exosomes/extracellular vesicles that have demonstrated the ability to fuse with cell membranes and deliver intracellular cargo in a similar manner to natural exosomes. Bioxome can carry selected therapeutic cargo inside target cells, to induce a variety of therapeutic applications. Currently developed to treat Kidney and Liver Disorders.

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.

A regenerative approach to transform patient’s own liver cells into fully functional and physiologically glucose-responsive AIPs designed to provide long-term insulin independence. This potential treatment was awarded orphan drug designation by the FDA with aims to provide a practical cure for Total Pancreatectomy due to chronic pancreatitis.